This widening operating loss primarily reflects an increase in general and administrative expenses (+32.1 million euros to 47.9 million euros), driven notably by 20.3 million euros in share-based compensation charges.

As of December 31, 2025, the company's cash and cash equivalents stood at 99.3 million euros, with short-term deposits of 131.6 million euros, providing a cash runway to fund operations through the middle of the first quarter of 2027.

"Inventiva concludes the 2025 fiscal year with resources expected to fund our operations until the anticipated publication of the NATiV3 topline results later this year," highlighted CEO Andrew Obenshain.

"In line with the progress of our clinical and operational activities, we are now adjusting our reporting timeline for results to the fourth quarter of 2026," the biopharmaceutical company's executive continued.